<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40994705</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2048-8505</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Clinical kidney journal</Title><ISOAbbreviation>Clin Kidney J</ISOAbbreviation></Journal><ArticleTitle>Empagliflozin and fluid balance: results from the SiRENA project.</ArticleTitle><Pagination><StartPage>sfaf262</StartPage><MedlinePgn>sfaf262</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">sfaf262</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ckj/sfaf262</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Sodium-glucose co-transporter 2 inhibitors (SGLT2is) exert cardiorenal benefits in type 2 diabetes (T2D) and chronic kidney disease (CKD), possibly mediated by natriuresis and changes in fluid balance. We examined the effects of empagliflozin on fluid and electrolyte balance.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Employing a randomized, double-blind, placebo-controlled crossover design, we conducted three identical trials examining patients with T2D with and without CKD and non-diabetic CKD, respectively. A total of 49 participants were randomized to 4&#xa0;weeks of empagliflozin 10&#xa0;mg/day or matching placebo and crossed over to the opposite treatment after a wash-out. We measured body composition, 24-h ambulatory blood pressure (BP) and several markers of fluid and electrolyte balance.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">In the combined cohort, empagliflozin reduced extracellular body water by 0.29&#xa0;l [95% confidence interval (CI) -0.54 to -0.03, <i>P</i>&#xa0;=&#xa0;.03] and tended towards reducing overhydration [-0.23&#xa0;l (95% CI -0.51-0.05), <i>P</i>&#xa0;=&#xa0;.10]. Change in overhydration was correlated to changes in BP (<i>R</i>&#xa0;=&#xa0;0.38, <i>P</i>&#xa0;=&#xa0;.008). Sodium excretion and urine volume was unchanged, but copeptin, a surrogate of antidiuretic hormone (ADH), increased by 30% (<i>P</i>&#xa0;&gt;&#xa0;.0001), aquaporin-2 excretion increased by 8% (<i>P</i>&#xa0;=&#xa0;.04) and free water clearance decreased (<i>P</i>&#xa0;=&#xa0;.0001). Renin levels increased (<i>P</i>&#xa0;=&#xa0;.02) with non-significant increases in aldosterone (<i>P</i>&#xa0;=&#xa0;.05) and epithelial sodium channel excretion (<i>P</i>&#xa0;=&#xa0;.08).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">SGLT2i could exert diuretic effects that, although compensated for by increased ADH and renin-angiotensin-aldosterone system activity, causes lasting changes in fluid balance.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="UNASSIGNED">EU Clinical Trials Register 2019-004303-12, 2019-004447-80 and 2019-004467-50.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the ERA.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Flindt Nielsen</LastName><ForeName>Steffen</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0002-5410-1088</Identifier><AffiliationInfo><Affiliation>University Clinic in Nephrology and Hypertension, G&#xf8;dstrup Hospital, Herning, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Renal Medicine, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lundgreen Duus</LastName><ForeName>Camilla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University Clinic in Nephrology and Hypertension, G&#xf8;dstrup Hospital, Herning, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henrik Buus</LastName><ForeName>Niels</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-7972-8181</Identifier><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Renal Medicine, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>N&#xf8;rgaard Bech</LastName><ForeName>Jesper</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University Clinic in Nephrology and Hypertension, G&#xf8;dstrup Hospital, Herning, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holden Mose</LastName><ForeName>Frank</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-5830-5814</Identifier><AffiliationInfo><Affiliation>University Clinic in Nephrology and Hypertension, G&#xf8;dstrup Hospital, Herning, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Kidney J</MedlineTA><NlmUniqueID>101579321</NlmUniqueID><ISSNLinking>2048-8505</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CKD</Keyword><Keyword MajorTopicYN="N">SGLT2i</Keyword><Keyword MajorTopicYN="N">bioimpedance</Keyword><Keyword MajorTopicYN="N">diabetic kidney disease</Keyword><Keyword MajorTopicYN="N">renin&#x2013;angiotensin system</Keyword></KeywordList><CoiStatement>AstraZeneca has provided travel expenses for S.F.N. F.H.M. has participated on advisory boards and received speaker honoraria from Boehringer Ingelheim and AstraZeneca. J.B.N. has participated on advisory boards for Bayer, Boehringer Ingelheim and AstraZeneca. The remaining author declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>25</Day><Hour>4</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40994705</ArticleId><ArticleId IdType="pmc">PMC12455196</ArticleId><ArticleId IdType="doi">10.1093/ckj/sfaf262</ArticleId><ArticleId IdType="pii">sfaf262</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>

ElSayed &#xa0;NA, Aleppo &#xa0;G, Aroda &#xa0;VR &#xa0;et al.  &#xa0;9. Pharmacologic approaches to glycemic treatment: <i>Standards of Care in Diabetes&#x2014;2023</i>. Diabetes Care &#xa0;2023;46(Suppl 1):S140&#x2013;57. 10.2337/dc23-S009
</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc23-S009</ArticleId><ArticleId IdType="pmc">PMC9810476</ArticleId><ArticleId IdType="pubmed">36507650</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Disease: Improving Global Outcomes CKD Work Group . KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int &#xa0;2024;105(4S):S117&#x2013;314. 10.1016/j.kint.2023.10.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2023.10.018</ArticleId><ArticleId IdType="pubmed">38490803</ArticleId></ArticleIdList></Reference><Reference><Citation>DeFronzo &#xa0;RA, Hompesch &#xa0;M, Kasichayanula &#xa0;S &#xa0;et al. &#xa0;Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care &#xa0;2013;36:3169&#x2013;76. 10.2337/dc13-0387</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc13-0387</ArticleId><ArticleId IdType="pmc">PMC3781504</ArticleId><ArticleId IdType="pubmed">23735727</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallon &#xa0;V, Verma &#xa0;S. Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annu Rev Physiol &#xa0;2021;83:503&#x2013;28. 10.1146/annurev-physiol-031620-095920</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-physiol-031620-095920</ArticleId><ArticleId IdType="pmc">PMC8017904</ArticleId><ArticleId IdType="pubmed">33197224</ArticleId></ArticleIdList></Reference><Reference><Citation>Inzucchi &#xa0;SE, Zinman &#xa0;B, Fitchett &#xa0;D &#xa0;et al. &#xa0;How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME Trial. Diabetes Care &#xa0;2018;41:356&#x2013;63. 10.2337/dc17-1096</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc17-1096</ArticleId><ArticleId IdType="pubmed">29203583</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajasekeran &#xa0;H, Lytvyn &#xa0;Y, Cherney &#xa0;DZ. Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney Int &#xa0;2016;89:524&#x2013;6. 10.1016/j.kint.2015.12.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2015.12.038</ArticleId><ArticleId IdType="pubmed">26880444</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayne &#xa0;KJ, EMPA-KIDNEY Collaborative Group . Effects of empagliflozin on fluid overload, weight and blood pressure in CKD. J Am Soc Nephrol &#xa0;2023;34(11S):678. 10.1681/ASN.20233411S1678b</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.20233411S1678b</ArticleId><ArticleId IdType="pmc">PMC7615589</ArticleId><ArticleId IdType="pubmed">38082486</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansary &#xa0;TM, Nakano &#xa0;D, Nishiyama &#xa0;A. Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system. Int J Mol Sci &#xa0;2019;20:629. 10.3390/ijms20030629</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20030629</ArticleId><ArticleId IdType="pmc">PMC6387046</ArticleId><ArticleId IdType="pubmed">30717173</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka &#xa0;H, Takano &#xa0;K, Iijima &#xa0;H &#xa0;et al. &#xa0;Factors affecting canagliflozin-induced transient urine volume increase in patients with type 2 diabetes mellitus. Adv Ther &#xa0;2017;34:436&#x2013;51. 10.1007/s12325-016-0457-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-016-0457-8</ArticleId><ArticleId IdType="pmc">PMC5331075</ArticleId><ArticleId IdType="pubmed">27981497</ArticleId></ArticleIdList></Reference><Reference><Citation>Iijima &#xa0;H, Kifuji &#xa0;T, Maruyama &#xa0;N &#xa0;et al. &#xa0;Pharmacokinetics, pharmacodynamics, and safety of canagliflozin in Japanese patients with type 2 diabetes mellitus. Adv Ther &#xa0;2015;32:768&#x2013;82. 10.1007/s12325-015-0234-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-015-0234-0</ArticleId><ArticleId IdType="pmc">PMC4569680</ArticleId><ArticleId IdType="pubmed">26280756</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrannini &#xa0;E, Baldi &#xa0;S, Frascerra &#xa0;S &#xa0;et al. &#xa0;Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care &#xa0;2017;40:771&#x2013;6. 10.2337/dc16-2724</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc16-2724</ArticleId><ArticleId IdType="pubmed">28325783</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholtes &#xa0;RA, Muskiet &#xa0;MHA, van Baar &#xa0;MJB &#xa0;et al. &#xa0;Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT Trial. Diabetes Care &#xa0;2021;44:440&#x2013;7. 10.2337/dc20-2604</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc20-2604</ArticleId><ArticleId IdType="pmc">PMC7818331</ArticleId><ArticleId IdType="pubmed">33318125</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallon &#xa0;V. How can inhibition of glucose and sodium transport in the early proximal tubule protect the cardiorenal system? &#xa0;Nephrol Dial Transplant &#xa0;2024;39:1565&#x2013;73. 10.1093/ndt/gfae060</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfae060</ArticleId><ArticleId IdType="pmc">PMC11427065</ArticleId><ArticleId IdType="pubmed">38439675</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcox &#xa0;CS, Shen &#xa0;W, Boulton &#xa0;DW &#xa0;et al. &#xa0;Interaction between the sodium-glucose-linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects. J Am Heart Assoc &#xa0;2018;7:e007046. 10.1161/JAHA.117.007046</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.117.007046</ArticleId><ArticleId IdType="pmc">PMC5850181</ArticleId><ArticleId IdType="pubmed">29440005</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomson &#xa0;SC, Rieg &#xa0;T, Miracle &#xa0;C &#xa0;et al. &#xa0;Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol &#xa0;2012;302:R75&#x2013;83. 10.1152/ajpregu.00357.2011</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpregu.00357.2011</ArticleId><ArticleId IdType="pmc">PMC3349378</ArticleId><ArticleId IdType="pubmed">21940401</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahena-Lopez &#xa0;JP, Rojas-Vega &#xa0;L, Ch&#xe1;vez-Canales &#xa0;M &#xa0;et al. &#xa0;Glucose/fructose delivery to the distal nephron activates the sodium-chloride cotransporter via the calcium-sensing receptor. J Am Soc Nephrol &#xa0;2023;34:55&#x2013;72. 10.1681/ASN.2021121544</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2021121544</ArticleId><ArticleId IdType="pmc">PMC10101570</ArticleId><ArticleId IdType="pubmed">36288902</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen &#xa0;T, Scholtes &#xa0;R, Greasley &#xa0;PJ. &#xa0;et al. &#xa0;Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: results from DAPASALT and DIAMOND. Diabetes Obesity Metabolism &#xa0;2022;24:1578&#x2013;87. 10.1111/dom.14729</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.14729</ArticleId><ArticleId IdType="pmc">PMC9262818</ArticleId><ArticleId IdType="pubmed">35478433</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen &#xa0;SF, Duus &#xa0;CL, Buus &#xa0;NH &#xa0;et al. &#xa0;Effects of empagliflozin in type 2 diabetes with and without chronic kidney disease and nondiabetic chronic kidney disease: protocol for 3 crossover randomized controlled trials (SiRENA Project). JMIR Res Protoc &#xa0;2024;13:e56067. 10.2196/56067</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/56067</ArticleId><ArticleId IdType="pmc">PMC11170048</ArticleId><ArticleId IdType="pubmed">38680116</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen &#xa0;SF, Duus &#xa0;CL, Buus &#xa0;NH &#xa0;et al. &#xa0;Randomized, placebo-controlled trial on the renal and systemic hemodynamic effects of empagliflozin. Kidney Int Rep &#xa0;2025;10:134&#x2013;44. 10.1016/j.ekir.2024.10.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2024.10.019</ArticleId><ArticleId IdType="pmc">PMC11725969</ArticleId><ArticleId IdType="pubmed">39810756</ArticleId></ArticleIdList></Reference><Reference><Citation>Mose &#xa0;FH, Larsen &#xa0;T, Bech &#xa0;JN &#xa0;et al. &#xa0;Effects of atorvastatin on systemic and renal nitric oxide in healthy man. Clin Exp Hypertens &#xa0;2013;35:148&#x2013;57. 10.3109/10641963.2012.702835</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10641963.2012.702835</ArticleId><ArticleId IdType="pubmed">22784101</ArticleId></ArticleIdList></Reference><Reference><Citation>Mose &#xa0;FH, Oczachowska&#x2010;Kulik &#xa0;AE, Fenton &#xa0;RA &#xa0;et al. &#xa0;Effect of furosemide on body composition and urinary proteins that mediate tubular sodium and sodium transport&#x2014;a randomized controlled trial. Physiol Rep &#xa0;2021;8:e14653. 10.14814/phy2.14653</Citation><ArticleIdList><ArticleId IdType="doi">10.14814/phy2.14653</ArticleId><ArticleId IdType="pmc">PMC7757674</ArticleId><ArticleId IdType="pubmed">33356004</ArticleId></ArticleIdList></Reference><Reference><Citation>Graffe &#xa0;CC, Bech &#xa0;JN, Pedersen &#xa0;EB. Effect of high and low sodium intake on urinary aquaporin-2 excretion in healthy humans. Am J Physiol Renal Physiol &#xa0;2012;302:F264&#x2013;75. 10.1152/ajprenal.00442.2010</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajprenal.00442.2010</ArticleId><ArticleId IdType="pubmed">21993890</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen &#xa0;RS, Bentzen &#xa0;H, Bech &#xa0;JN &#xa0;et al. &#xa0;Effect of water deprivation and hypertonic saline infusion on urinary AQP2 excretion in healthy humans. Am J Physiol Renal Physiol &#xa0;2001;280:F860&#x2013;7. 10.1152/ajprenal.2001.280.5.F860</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajprenal.2001.280.5.F860</ArticleId><ArticleId IdType="pubmed">11292629</ArticleId></ArticleIdList></Reference><Reference><Citation>Moissl &#xa0;UM, Wabel &#xa0;P, Chamney &#xa0;PW &#xa0;et al. &#xa0;Body fluid volume determination via body composition spectroscopy in health and disease. Physiol Meas &#xa0;2006;27:921&#x2013;33. 10.1088/0967-3334/27/9/012</Citation><ArticleIdList><ArticleId IdType="doi">10.1088/0967-3334/27/9/012</ArticleId><ArticleId IdType="pubmed">16868355</ArticleId></ArticleIdList></Reference><Reference><Citation>Chamney &#xa0;PW, Wabel &#xa0;P, Moissl &#xa0;UM &#xa0;et al. &#xa0;A whole-body model to distinguish excess fluid from the hydration of major body tissues. Am J Clin Nutr &#xa0;2007;85:80&#x2013;9. 10.1093/ajcn/85.1.80</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/85.1.80</ArticleId><ArticleId IdType="pubmed">17209181</ArticleId></ArticleIdList></Reference><Reference><Citation>Schork &#xa0;A, Eberbach &#xa0;M-L, Bohnert &#xa0;BN &#xa0;et al. &#xa0;SGLT2 inhibitors decrease overhydration and proteasuria in patients with chronic kidney disease: a longitudinal observational study. Kidney Blood Press Res &#xa0;2024;49:124&#x2013;34. 10.1159/000535643</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000535643</ArticleId><ArticleId IdType="pmc">PMC10885839</ArticleId><ArticleId IdType="pubmed">38228104</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholtes &#xa0;RA, Mosterd &#xa0;CM, Hesp &#xa0;AC &#xa0;et al. &#xa0;Mechanisms underlying the blood pressure-lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: a secondary analysis of a randomized crossover trial. Diabetes Obes Metab &#xa0;2023;25:198&#x2013;207. 10.1111/dom.14864</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.14864</ArticleId><ArticleId IdType="pmc">PMC10087931</ArticleId><ArticleId IdType="pubmed">36089810</ArticleId></ArticleIdList></Reference><Reference><Citation>Heerspink &#xa0;HJ, Provenzano &#xa0;M, Vart &#xa0;P &#xa0;et al. &#xa0;Dapagliflozin and blood pressure in patients with chronic kidney disease and albuminuria. Am Heart J &#xa0;2024;270:125&#x2013;35 . 10.1016/j.ahj.2024.02.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2024.02.006</ArticleId><ArticleId IdType="pubmed">38367893</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristensen &#xa0;DK, Mose &#xa0;FH, Buus &#xa0;NH &#xa0;et al. &#xa0;SGLT2 inhibition improves endothelium-independent vasodilatory function in type 2 diabetes: a double-blind, randomized, placebo-controlled crossover trial. Diabetes Obes Metab &#xa0;2025;27:1123&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">39610328</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka &#xa0;K, Masuda &#xa0;T, Ohara &#xa0;K &#xa0;et al. &#xa0;Fluid homeostatic action of dapagliflozin in patients with chronic kidney disease: the DAPA-BODY Trial. Front Med &#xa0;2023;10:1287066. 10.3389/fmed.2023.1287066</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1287066</ArticleId><ArticleId IdType="pmc">PMC10753517</ArticleId><ArticleId IdType="pubmed">38155663</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinnunen &#xa0;P, Vuolteenaho &#xa0;O, Ruskoaho &#xa0;H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology &#xa0;1993;132:1961&#x2013;70. 10.1210/endo.132.5.8477647</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/endo.132.5.8477647</ArticleId><ArticleId IdType="pubmed">8477647</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai &#xa0;Y-C, Tsai &#xa0;H-J, Lee &#xa0;C-S &#xa0;et al. &#xa0;The interaction between N-terminal pro-brain natriuretic peptide and fluid status in adverse clinical outcomes of late stages of chronic kidney disease. PLoS One &#xa0;2018;13:e0202733. 10.1371/journal.pone.0202733</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0202733</ArticleId><ArticleId IdType="pmc">PMC6105012</ArticleId><ArticleId IdType="pubmed">30133531</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanner &#xa0;C, Nangaku &#xa0;M, Kraus &#xa0;BJ &#xa0;et al. &#xa0;How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial. Nephrol Dial Transplant &#xa0;2024;39:1504&#x2013;13. 10.1093/ndt/gfae032</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfae032</ArticleId><ArticleId IdType="pmc">PMC11361804</ArticleId><ArticleId IdType="pubmed">38323492</ArticleId></ArticleIdList></Reference><Reference><Citation>Eickhoff &#xa0;MK, Dekkers &#xa0;CCJ, Kramers &#xa0;BJ &#xa0;et al. &#xa0;Effects of dapagliflozin on volume status when added to renin-angiotensin system inhibitors. J Clin Med &#xa0;2019;8:779. 10.3390/jcm8060779</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm8060779</ArticleId><ArticleId IdType="pmc">PMC6616433</ArticleId><ArticleId IdType="pubmed">31159350</ArticleId></ArticleIdList></Reference><Reference><Citation>van Bommel &#xa0;EJM, Muskiet &#xa0;MHA, van Baar &#xa0;MJB &#xa0;et al. &#xa0;The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int &#xa0;2020;97:202&#x2013;12. 10.1016/j.kint.2019.09.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2019.09.013</ArticleId><ArticleId IdType="pubmed">31791665</ArticleId></ArticleIdList></Reference><Reference><Citation>Manosroi &#xa0;W, Danpanichkul &#xa0;P, Atthakomol &#xa0;P. Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone and renin levels in diabetes mellitus type 2 patients: a systematic review and meta-analysis. Sci Rep &#xa0;2022;12:19603. 10.1038/s41598-022-24280-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-24280-9</ArticleId><ArticleId IdType="pmc">PMC9666660</ArticleId><ArticleId IdType="pubmed">36380013</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown &#xa0;MJ. Renin: friend or foe? &#xa0;Heart &#xa0;2007;93:1026&#x2013;33. 10.1136/hrt.2006.107706</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/hrt.2006.107706</ArticleId><ArticleId IdType="pmc">PMC1955008</ArticleId><ArticleId IdType="pubmed">17488768</ArticleId></ArticleIdList></Reference><Reference><Citation>Persson &#xa0;AEG, Ollerstam &#xa0;A, Liu &#xa0;R &#xa0;et al. &#xa0;Mechanisms for macula densa cell release of renin. Acta Physiol Scand &#xa0;2004;181:471&#x2013;4. 10.1111/j.1365-201X.2004.01320.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-201X.2004.01320.x</ArticleId><ArticleId IdType="pubmed">15283760</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherney &#xa0;DZI, Perkins &#xa0;BA, Soleymanlou &#xa0;N &#xa0;et al. &#xa0;Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation &#xa0;2014;129:587&#x2013;97. 10.1161/CIRCULATIONAHA.113.005081</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.113.005081</ArticleId><ArticleId IdType="pubmed">24334175</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuen &#xa0;BL, Oshima &#xa0;M, Agarwal &#xa0;R &#xa0;et al. &#xa0;Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized controlled trials. Circulation &#xa0;2022;145:1460&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">35394821</ArticleId></ArticleIdList></Reference><Reference><Citation>Berton &#xa0;AM, Parasiliti-Caprino &#xa0;M, Prencipe &#xa0;N &#xa0;et al. &#xa0;Copeptin adaptive response to SGLT2 inhibitors in patients with type 2 diabetes mellitus: the GliRACo study. Front Neurosci &#xa0;2023;17:1098404. 10.3389/fnins.2023.1098404</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2023.1098404</ArticleId><ArticleId IdType="pmc">PMC10067557</ArticleId><ArticleId IdType="pubmed">37021137</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholtes &#xa0;RA, Muskiet &#xa0;MHA, van Baar &#xa0;MJB &#xa0;et al. &#xa0;The adaptive renal response for volume homeostasis during 2 weeks of dapagliflozin treatment in people with type 2 diabetes and preserved renal function on a sodium-controlled diet. Kidney Int Rep &#xa0;2022;7:1084&#x2013;92. 10.1016/j.ekir.2022.02.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2022.02.023</ArticleId><ArticleId IdType="pmc">PMC9091605</ArticleId><ArticleId IdType="pubmed">35570989</ArticleId></ArticleIdList></Reference><Reference><Citation>Wabel &#xa0;P, Chamney &#xa0;P, Moissl &#xa0;U &#xa0;et al. &#xa0;Importance of whole-body bioimpedance spectroscopy for the management of fluid balance. Blood Purif &#xa0;2009;27:75&#x2013;80. 10.1159/000167013</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000167013</ArticleId><ArticleId IdType="pmc">PMC2813803</ArticleId><ArticleId IdType="pubmed">19169022</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>